Three newly approved drugs for chronic lymphocytic leukemia (CLL): Incorporating ibrutinib, idelalisib and obinutuzumab into clinical practice

von Sanford, David, Wierda, William G., Burger, Jan A., Keating, Michael J., O’Brien, Susan M.
Veröffentlicht in Clin Lymphoma Myeloma Leuk (2015)

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

von O'Brien, Susan M., Claxton, David F., Crump, Michael, Faderl, Stefan, Kipps, Thomas, Keating, Michael J., Viallet, Jean, Cheson, Bruce D.
Veröffentlicht in Blood (2009)

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia

von Strati, Paolo, Keating, Michael J., Burger, Jan A., O’Brien, Susan M., Wierda, William G., Estrov, Zeev, Zacharian, Gracy, Ferrajoli, Alessandra
Veröffentlicht in Haematologica (2017)

Fludarabine, Cyclophosphamide, and Multiple-Dose Rituximab as Frontline Therapy for Chronic Lymphocytic Leukemia

von Short, Nicholas J., Keating, Michael J., Wierda, William G., Faderl, Stefan, Ferrajoli, Alessandra, Estrov, Zeev, Smith, Susan C., O'Brien, Susan M.
Veröffentlicht in Cancer (2015)

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

von Strati, Paolo, Keating, Michael J., O’Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan, Faderl, Stefan, Tambaro, Francesco Paolo, Jain, Nitin, Wierda, William G.
Veröffentlicht 2014

Outcomes of patients with CLL treated with first line idelalisib plus rituximab after cessation of treatment for toxicity

von Thompson, Philip A, Stingo, Francesco, Keating, Michael J, Ferrajoli, Alessandra, Burger, Jan A., Wierda, William G, Kadia, Tapan M, O’Brien, Susan M.
Veröffentlicht in Cancer (2016)

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

von Cheson, Bruce D., Byrd, John C., Rai, Kanti R., Kay, Neil E., O'Brien, Susan M., Flinn, Ian W., Wiestner, Adrian, Kipps, Thomas J.
Veröffentlicht 2012

Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

von Badoux, Xavier C., Keating, Michael J., Wen, Sijin, Wierda, William G., O'Brien, Susan M., Faderl, Stefan, Sargent, Rachel, Burger, Jan A., Ferrajoli, Alessandra
Veröffentlicht in J Clin Oncol (2013)

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

von Chen, Qiushi, Jain, Nitin, Ayer, Turgay, Wierda, William G., Flowers, Christopher R., O’Brien, Susan M., Keating, Michael J., Kantarjian, Hagop M., Chhatwal, Jagpreet
Veröffentlicht in J Clin Oncol (2017)

β(2)-microglobulin Normalization Within 6 months of Ibrutinib-based Treatment is Associated with Superior PFS in CLL

von Thompson, Philip A., O’Brien, Susan M., Xiao, Lianchun, Wang, Xuemei, Burger, Jan A., Jain, Nitin, Ferrajoli, Alessandra, Estrov, Zeev, Keating, Michael J., Wierda, William G.
Veröffentlicht in Cancer (2015)

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

von Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Veröffentlicht 2011

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

von Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Veröffentlicht 2011

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

von Thompson, Philip A., Tam, Constantine S., O’Brien, Susan M., Wierda, William G., Stingo, Francesco, Plunkett, William, Smith, Susan C., Kantarjian, Hagop M., Freireich, Emil J., Keating, Michael J.
Veröffentlicht in Blood (2016)

Soluble syndecan-1 (sCD138) as a prognostic factor independent of IgVH mutation status in patients with chronic lymphocytic leukemia

von Jilani, Iman, Wei, Caimiao, Bekele, B. Nebiyou, Zhang, Zhong J, Keating, Michael, Wierda, William, Ferrajoli, Alessandra, Estrov, Zeev, Kantarjian, Hagop, O'Brien, Susan M, Giles, Francis J, Albitar, Maher
Veröffentlicht 2008

Self-Administered, Subcutaneous Alemtuzumab to Treat Residual Disease in Patients With Chronic Lymphocytic Leukemia

von Wierda, William G., Kipps, Thomas J., Keating, Michael J., Brown, Jennifer R., Gribben, John G., Browning, Mary, Rassenti, Laura Z., Greaves, Andrew W., Neuberg, Donna, O’Brien, Susan M.
Veröffentlicht in Cancer (2010)

The Addition of CD20 Monoclonal Antibodies to Lenalidomide Improves Response Rates and Survival in Relapsed/refractory patients with CLL Relative to Lenalidomide Monotherapy – The...

von Thompson, Philip A., Rosovski, Uri, Keating, Michael J., Stingo, Francesco, Smith, Susan C., Wierda, William G., Falchi, Lorenzo, O'Brien, Susan M., Estrov, Zeev, Burger, Jan A., Ferrajoli, Alessandra
Veröffentlicht in Br J Haematol (2015)

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

von Strati, Paolo, Keating, Michael J., O'Brien, Susan M., Burger, Jan, Ferrajoli, Alessandra, Jain, Nitin, Tambaro, Francesco Paolo, Estrov, Zeev, Jorgensen, Jeffrey, Challagundla, Pramoda, Faderl, Stefan H., Wierda, William G.
Veröffentlicht 2014

Complex Karyotype is a Stronger Predictor than Del(17p) for Inferior Outcome in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens

von Thompson, Philip A., O’Brien, Susan M., Wierda, William G., Ferrajoli, Alessandra, Stingo, Francesco, Smith, Susan C., Burger, Jan A., Estrov, Zeev, Jain, Nitin, Kantarjian, Hagop M., Keating, Michael J.
Veröffentlicht in Cancer (2015)

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

von Badoux, Xavier C., Keating, Michael J., Wen, Sijin, Lee, Bang-Ning, Sivina, Mariela, Reuben, James, Wierda, William G., O'Brien, Susan M., Faderl, Stefan, Kornblau, Steven M., Burger, Jan A., Ferrajoli, Alessandra
Veröffentlicht 2011

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

von Short, Nicholas J., Jabbour, Elias, Sasaki, Koji, Patel, Keyur, O’Brien, Susan M., Cortes, Jorge E., Garris, Rebecca, Issa, Ghayas C., Garcia-Manero, Guillermo, Luthra, Rajyalakshmi, Thomas, Deborah, Kantarjian, Hagop, Ravandi, Farhad
Veröffentlicht in Blood (2016)